These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 19527632

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
    Newton HB.
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
    [Abstract] [Full Text] [Related]

  • 25. VEGF as a therapeutic target in cancer.
    Ferrara N.
    Oncology; 2005 Dec; 69 Suppl 3():11-6. PubMed ID: 16301831
    [Abstract] [Full Text] [Related]

  • 26. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
    Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D.
    Curr Med Chem; 2006 Dec; 13(16):1845-57. PubMed ID: 16842197
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
    Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, Fox SB.
    J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
    [Abstract] [Full Text] [Related]

  • 29. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.
    van der Meel R, Symons MH, Kudernatsch R, Kok RJ, Schiffelers RM, Storm G, Gallagher WM, Byrne AT.
    Drug Discov Today; 2011 Mar; 16(5-6):219-28. PubMed ID: 21262381
    [Abstract] [Full Text] [Related]

  • 30. Drug insight: VEGF as a therapeutic target for breast cancer.
    Schneider BP, Sledge GW.
    Nat Clin Pract Oncol; 2007 Mar; 4(3):181-9. PubMed ID: 17327858
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
    Tie J, Desai J.
    Crit Rev Oncog; 2012 Mar; 17(1):51-67. PubMed ID: 22471664
    [Abstract] [Full Text] [Related]

  • 37. Angiogenesis regulated by VEGF and its receptors and its clinical application.
    Shibuya M.
    Rinsho Ketsueki; 2009 May; 50(5):404-12. PubMed ID: 19483401
    [No Abstract] [Full Text] [Related]

  • 38. Challenges for patient selection with VEGF inhibitors.
    Longo R, Gasparini G.
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):151-70. PubMed ID: 17370072
    [Abstract] [Full Text] [Related]

  • 39. Inhibitors of the vascular endothelial growth factor receptor.
    Rosen LS.
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1173-87. PubMed ID: 12512388
    [Abstract] [Full Text] [Related]

  • 40. Anti-vascular endothelial growth factor therapy in the era of personalized medicine.
    Féliz LR, Tsimberidou AM.
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):1-12. PubMed ID: 23463481
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.